Matrigel modulates a stem cell phenotype and promotes tumor cell formation in a mantle cell lymphoma cell line by Hielscher, Abigail et al.
Philadelphia College of Osteopathic Medicine
DigitalCommons@PCOM
PCOM Scholarly Papers
2013
Matrigel modulates a stem cell phenotype and
promotes tumor cell formation in a mantle cell
lymphoma cell line
Abigail Hielscher
Philadelphia College of Osteopathic Medicine, abigailhi@pcom.edu
Timothy McGuire
Dennis Weisenburger
John Graham Sharp
Follow this and additional works at: http://digitalcommons.pcom.edu/scholarly_papers
Part of the Cancer Biology Commons
This Article is brought to you for free and open access by DigitalCommons@PCOM. It has been accepted for inclusion in PCOM Scholarly Papers by
an authorized administrator of DigitalCommons@PCOM. For more information, please contact library@pcom.edu.
Recommended Citation
Hielscher, Abigail; McGuire, Timothy; Weisenburger, Dennis; and Sharp, John Graham, "Matrigel modulates a stem cell phenotype
and promotes tumor cell formation in a mantle cell lymphoma cell line" (2013). PCOM Scholarly Papers. Paper 860.
http://digitalcommons.pcom.edu/scholarly_papers/860
Vol.3, No.3, 167-179 (2013)                                                               Stem Cell Discovery 
http://dx.doi.org/10.4236/scd.2013.33022  
Matrigel modulates a stem cell phenotype and  
promotes tumor formation in a mantle cell lymphoma 
cell line 
Abigail Hielscher1, Timothy McGuire2, Dennis Weisenburger3, John Graham Sharp4* 
 
1Department of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, USA 
2School of Pharmacy, University of Nebraska Medical Center, Omaha, USA 
3Department of Pathology, City of Hope Medical Center, Duarte, USA 
4Department of Cell Biology, Genetics and Anatomy, University of Nebraska Medical Center, Omaha, USA; 
*Corresponding Author: jsharp@unmc.edu 
 
Received 27 March 2013; revised 27 April 2013; accepted 27 May 2013 
 
Copyright © 2013 Abigail Hielscher et al. This is an open access article distributed under the Creative Commons Attribution License, 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 
ABSTRACT 
Tumors may be maintained by subpopulations 
of cells possessing stem cell-like properties. We 
evaluated the stem cell-like and tumor-forming 
properties of side population (SP) and CD133+/ 
CD44+ cells in Granta 519, a human mantle cell 
lymphoma cell line. The in-vitro Cobblestone 
Area Forming Cell (CAFC) assay, designed to 
detect stem and progenitor cells, revealed that 
SP cells contained the greatest proportion of 
stem cell-like cells. The addition of Matrigel to 
CAFC assays of SP and non-SP cells both in- 
creased their respective stem cell frequencies in 
comparison to those cultures without Matrigel, 
and additionally resulted in observed stem cell 
frequencies which were the same between SP 
and non-SP cells. Contrary, Matrigel decreased 
the stem cell frequencies of CD133+/CD44+ or 
CD133−/CD44− cells. In-vivo assays revealed tu- 
mor formation from Matrigel-mixed SP and non- 
SP cells, and in one instance, occurred with as 
few as one Matrigel-mixed SP cell. Vehicle-mixed 
injections of SP and non-SP tumor cells resulted 
in tumor formation from SP cells only. Tumor 
formation did not occur from Matrigel nor hya- 
luronan (cellular substrate for CD44-expressing 
cells)-mixed populations of CD133+/CD44+ or 
CD133−/CD44− cells. These data demonstrate 
that Matrigel modulates a stem cell phenotype 
and promotes tumor formation from SP and non- 
SP cells. The tumor micro-environmental niche 
and tumor cell to micro-environmental interac- 
tions may be important future targets for novel 
chemotherapeutic agents. 
 
Keywords: Mantle Cell Lymphoma; Side Population; 
Tumor-Initiating Cells; Microenvironment 
1. INTRODUCTION 
Mantle cell lymphoma (MCL) is a type of non-Hodg- 
kin’s Lymphoma, characterized by an aberrant prolifera- 
tion of mature B lymphocytes in the mantle zones of 
lymphoid follicles. The disease has an aggressive clinical 
course with a median patient survival of only 3 - 4 years 
following diagnosis [1,2]. This dismal outcome is due to 
the advanced stage of disease upon diagnosis with sev- 
eral extranodal sites typically involved including the 
spleen [3], bone marrow [4] and gastrointestinal tract [5]. 
Although a wide variety of chemotherapeutic agents are 
presently available to treat the disease, such therapeutic 
strategies have not significantly improved patient out- 
come [6-8] with patient relapse being a frequent occur- 
rence [9,10]. Due to the aggressive nature of the disease 
and the high propensity for relapse, novel approaches for 
identifying the cell type(s) responsible for MCL initia- 
tion and progression are imperative for understanding 
and better combating the disease.  
Increasing evidence has pointed to the existence of 
subsets of tumor cells proposed to be responsible for 
tumor initiation and propagation. Such tumor cells are 
referred to as tumor-initiating cells (TICs), rare sub- 
populations of tumor cells capable of tumor initiation 
when introduced in small numbers into immunocom- 
promised mice, self-renewal upon serial transplantation 
into immunocompromised mice and differentiation into 
cells making up the bulk of the original tumor [11]. First 
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described by Bonnet et al [12] in human leukemias, TICs 
have since been discovered in solid tumors including 
breast [13], prostate [14,15], colorectal [16], and liver 
carcinomas [17,18] amongst others. Regarding lympho- 
mas, TICs have been identified in a mouse model of 
MCL [19] and have recently been prospectively identi- 
fied in human MCL tumors [20]. In the latter study, it 
was reported that MCL cells lacking the mature B cell 
surface receptor CD19 were enriched for self-renewal 
and tumor-forming capabilities following xenotransplan- 
tation in immunodeficient animals [20]. Additional in- 
vestigation is warranted to further define and character- 
ize this population of putative MCL TICs so as to better 
identify and design chemotherapeutic agents aimed at 
eliminating these potentially rare and aggressive MCL 
subpopulations.  
Validated methods, similar to those employed for tis-
sue stem cells, are required for isolation and evaluation 
of putative MCL TICs. Such methods include the use of 
cell surface markers, aldehyde dehydrogenase activity, or 
the presence of a side population (SP). Of particular in- 
terest is the cell surface marker CD133, a hematopoietic 
stem cell (HSC) marker [21], and CD44, a cell surface 
adhesion receptor which facilitates cellular attachment to 
the extracellular matrix (ECM) [22,23]. Both CD133 and 
CD44, alone or in conjunction with other cell surface 
markers, have been assigned to cells having enhanced 
tumorigenic and stem cell-like properties [14-16,18,24]. 
The second cell population evaluated is the SP, a tail- 
shaped cell population visualized as a result of ABCG2- 
mediated efflux of the Hoechst 33342 dye [25]. First 
described by Goodell et al. [26] as a novel method for 
isolating HSCs from murine bone marrow, the SP has 
been employed to isolate both tissue stem cells [27] and 
putative TIC populations [11,17,19,20].  
Tissue stem cells are known to reside in supportive 
niches or microenvironments, comprised of cellular and 
non-cellular components which together maintain stem 
cell homeostasis [28,29]. It is possible that the enhanced 
tumorigenicity and stem cell-like properties of TICs may 
be a result of their maintenance in supportive micro-en- 
vironmental niches. Indeed, Vermeulen et al. [30] re- 
ported that the microenvironment was imperative for 
regulating Wnt activity, functionally assigned to colon 
TICs. Similarly, Calabrese et al. [31] discovered that 
brain TICs were localized to the brain vascular niche, 
which they demonstrated to be responsible for promoting 
self-renewal and accelerating tumor growth from brain 
TICs. Regarding lymphomas, it has been demonstrated 
that the lymph node microenvironment actively partici- 
pates in the progression of follicular lymphoma [32].  
In the present study, we sought to determine whether 
microenvironmental factors were necessary for acceler- 
ating self-renewal and tumor-formation capabilities of 
Granta MCL TICs isolated on the basis of either CD133/ 
CD44 co-expression or the SP functional pheno-type. 
While the stem cell niche is comprised of numerous cel- 
lular and non-cellular entities, the ECM is of particular 
interest as it is known to play an important role in regu- 
lating stem cell self-renewal and differentiation [33-37]. 
As such, we elected to utilize Matrigel, a commercially 
available conglomerate of ECM proteins derived from a 
murine sarcoma. Matrigel served as a biological sub- 
strate to promote MCL TIC xenograft tumor formation, 
previously demonstrated by others [38-40]. We demon- 
strate that Matrigel, rather than cell phenotype differ- 
ences, affect the enrichment of stem cell-like cells in- 
vitro and expedite tumor development in-vivo for both 
SP and non-SP cells. Elucidating the role whereby the 
tumor microenvironment influences proposed MCL TIC 
behaviors is imperative for implementation of better and/ 
or novel therapeutics targeted toward both the tumor 
microenvironment and MCL to niche interactions.  
2. MATERIALS AND METHOD 
2.1. Cell Lines and Culture 
Granta 519 (herein, Granta) cells were kindly obtained 
from Dr. Shantaram Joshi, UNMC and cultured in 
DMEM (Invitrogen; Grand Island, NY) containing 10% 
fetal bovine serum (FBS) and 1× penicillin/streptomycin 
(Invitrogen). Murine bone marrow stromal cells (MS5) 
[41] were kindly provided by Dr. John Jackson (Wake 
Forest Institute of Regenerative Medicine, Winston Sa- 
lem, NC) and employed as described previously [42]. 
MS5 were cultured in RPMI (Invitrogen) containing 10% 
FBS, 1× penicillin/streptomycin and 1 μg/ml hydrocorti- 
sone (Sigma-Aldrich; Allentown, PA). MS5 cells were 
rendered non-adherent with 0.05% trypsin/EDTA (Invi- 
trogen). Granta and MS5 cells were passaged every 2 - 3 
days and were maintained at 37˚C in a humidified air 
atmosphere containing 5% CO2. 
2.2. Flow Cytometry and Sorting 
Granta cells were stained 1:11 with PE-CD133 
(Miltenyi; Gergisch Gladbach, Germany) and 1:89 with 
APC-CD44 (e-Bioscience; San Diego, CA) for 20 min- 
utes at 4˚C. For SP analyses, Granta cells were re-sus- 
pended in 1 ml of Hoechst IMDM (Invitrogen; IMDM 
media supplemented with 2% FBS, 1μM Hepes, and 1x 
penicillin/streptomycin) for incubation at 4˚C overnight, 
adjusted to 1.0 × 106 cells/ml and stained with 6μg/ml 
Hoechst 33342 (Sigma-Aldrich) at 37˚C for 30 minutes. 
For confirmation of the SP, Granta cells were stained 
with 40 μM of verapamil (Sigma-Aldrich) for 15 minutes 
at 37˚C prior to incubation with Hoechst 33342. Analy- 
ses were conducted in the cell analysis facilities at 
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UNMC and Creighton University, Omaha, NE. Data was 
analyzed using FlowJoTM. Granta TIC and non-TIC cells 
were isolated using Fluorescence Activated Cell Sorting 
(FACS).  
2.3. Cobblestone Area Forming Cells  
Assays 
Granta populations were sorted in limiting dilutions 
into 96 well plates containing Murine Stromal 5 (MS5) 
cells. CD133+/CD44+ and CD133−/CD44− populations 
were adjusted to six dilutions ranging from 407 to 1 cell/ 
well. SP and non-SP populations were adjusted to 10 
dilutions ranging from 33,300 to 1 cell/well. All dilu- 
tions were made at a factor of 3 with each dilution being 
conducted in a total of 20 or 30 wells. In some instances, 
Granta populations were overlaid with a final concentra- 
tion of 275 μg/ml of Matrigel (BD Biosciences; San Jose, 
CA). The co-cultures were maintained for 5 weeks. 
Phase contrast microscopy was used to assess for the 
presence of phase dark cobblestones (groups of 3 or 
more cells growing in a colony beneath the stromal 
layer). Using a semi-logarithmic scale, the frequency of 
stem cell-like cells in each population was plotted and 
measured as the inverse of the number of seeded cells 
corresponding to 37% negative wells [43]. Images were 
captured at 10× magnification using a Nikon P5000 
digital camera.  
2.4. Tumorsphere Assays 
Granta SP and non-SP fractions were sorted at dilu- 
tions of 1, 10, 100 and 1000 cells/well into 96 well plates 
containing 150 µl of DMEM/HamsF12 media supple- 
mented with either 20 ng/ml of bFGF (Invitrogen) and 20 
ng/ml of EGF (Invitrogen) or 20 ng/ml bFGF and 10 
ng/ml of EGF. Cultures were maintained for a total of 6 
weeks in a 95% humidified air atmosphere at 37˚C and 
5% CO2. The presence of tumorspheres was evaluated at 
weekly intervals using phase contrast microscopy at 20× 
magnification. Images were photographed using a Nikon 
P5000 digital camera.  
2.5. Enzyme-Linked Immunosorbent  
Assay 
Supernatant from Granta cells, MS5 cells, Granta/ 
MS5 co-cultures and Granta TIC and non-TIC/MS5 co- 
cultures were collected and quantified for interleukin 8 
(IL-8) using enzyme-linked immunosorbent assay 
(ELISA). The Quantikine Immunoassay Kit (R&D Sys- 
tems, Minneapolis, MN) was utilized and all procedures 
were followed according to the manufacturer’s protocol. 
The lower limit of sensitivity for the assay is 3.5 pg/ml 
with a dynamic range between 3.5 pg/ml and 2000 pg/ml. 
Intra-assay coefficient of variation ranges from 5.4% - 
6.5% and inter-assay coefficient of variation from 6.1% 
to 9.7%. For analyses of IL-8 secretion from Granta and 
MS5 cells, 2.0 × 106 cells/ml were used. These cultures 
were maintained for 3 days prior to collection of super- 
natants. The cells were then re-suspended in fresh media 
and maintained in culture for another 3 days prior to col- 
lection of additional supernatant. For Granta/MS5 co- 
cultures, 1.0 × 106 MS5 cells were plated and maintained 
as previously described. Once MS5 cells reached 75% 
confluency, 1.0 × 106 Granta cells were plated and grown 
in standard growth media as previously described. The 
supernatants from Granta/MS5 co-cultures were collect- 
ed at 1, 3, 7 and 14 day intervals for the assessment of 
IL-8 levels over time. All supernatant was passed 
through a 70 µM strainer for removal of residual cell 
debris. For each analysis, the supernatants from trip- 
licate cultures were evaluated. 
2.6. In-Vivo Analyses 
All procedures on animals were followed in compli-
ance with the UNMC Animal Care and Use Committee. 
Three-five animals were maintained in a stainless steel 
cage and were given food and water ad libitum. Granta 
TIC and non-TIC populations were subcutaneously in- 
jected into the hind flanks of 3 - 5 week old female 
NOD-scid IL2Rgnull (NSG) mice (Jackson Laboratories; 
Bar Harbor, ME). Dilutions of 10, 100 and 1000 SP and 
non-SP cells and 10, 100 and 500 CD133+/CD44+ and 
CD133−/CD44− cells were prepared as described by 
Quintana et al (2008). Additionally, 10, 100 and 1000 
CD133+/CD44+ and CD133−/CD44− cells were resus- 
pended at a 1:8 dilution in hyaluronan (Hyaluronex; 
Lexington, KY). Single SP or non-SP cells were sorted 
using FACS into 96 well plates and were re-suspended at 
a 1:4 dilution in Matrigel. When tumors reached 1 - 1.5 
cm, animals were necropsied. Tumor volume was as- 
sessed using the formula for an ellipsoid: 4/3 πr1r2r3. As a 
control, Matrigel and vehicle were injected alone into 
either the right or left shoulders of 2 NSG mice.  
2.7. Histolopathology and Flow Cytometry 
Murine tissues including the lung, right femur, and 
kidney and portions of the spleen, small intestine, liver 
and kidney were fixed in 10% neutral buffered formalin 
for at least 24 hours and subjected to histopathological 
analysis using hematoxylin and eosin (H&E) staining 
(Eppley Cancer Center Histology Core Facility, UNMC). 
The remaining murine tissues were evaluated for human 
CD20 expression using flow cytometry. The lung was cut 
into 5 mm pieces and digested in 1 mg/ml collagenase V 
(Sigma-Aldrich) and 500 µg/ml elastase (Sigma-Aldrich) 
for 30 minutes at 37˚C. Bone marrow from the right fe- 
mur was extracted using a 22 gauge syringe. Remaining 
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tissues were subjected to mechanical disruption using a 
blunt end syringe. Tissues were filtered in 70 μM cell 
strainers. Between 3.0 × 105 and 1.0 × 106 cells were 
stained 1:11 with PE-CD20 (BD Biosciences). Flow cy- 
tometry assessed CD20 species cross-reactivity in the 
tissues from a control NSG mouse. H&E staining and SP 
analyses were performed as previously described.  
2.8. Statistical Analyses 
All data are presented as the mean ± SEM. Linear 
regression (Sigma Plot v 9.0; San Jose, CA) produced the 
line of best fit for CAFC assays. Graphs were made in 
Sigma Plot v 9.0 or GraphPad Prism v4.02 (GraphPad 
Software Inc. La Jolla, CA). Student’s t test was utilized 
for all remaining analyses. A P value ≤ 0.05 was con- 
sidered significant.  
3. RESULTS  
3.1. SP and CD133+/CD44+ Cells Are Present 
in Granta 
Initially, we sought to identify whether Granta cells 
possessed populations of cells, identified through use of 
Hoescht exclusion, (e.g. the SP) or expression of the he- 
matopoietic stem cell marker CD133 [21] in conjunction 
with CD44, widely used markers for identification of 
TICs [14-16,18,24]. The SP phenotype was observed in 
Granta and was represented at an average of 6.4% ± 
1.8% (range: 0% - 35.2%) (Figure 1(Aa)). Validation of 
the SP was confirmed through the incorporation of vera- 
pamil, an ABCG2 transport blocker (Figure 1(Ab)). 
Granta cells additionally possessed a small population of 
CD133+/CD44+ cells which represented 0.06% ± 0.03% 
(range: 0% - 0.39%) of the gated population. Examples 
of the unstained Granta control (Figure 1(Ac)) and 
Granta CD133+/CD44+ cells (Figure 1(Ad)) are shown. 
Overall, these analyses suggest that Granta possess sub- 
populations of cells bearing stem cell-like properties and 
points to the SP as being a more robust marker of puta- 
tive TICs.  
3.2. SP Cells Are Enriched for Cobblestone 
Area-Forming Cells 
The cobblestone area forming cell (CAFC) assay is 
considered one of the best in-vitro techniques for the 
identification of stem cells [44,45]. The presence of stem 
and progenitor cells is visualized when a stem or pro- 
genitor cell migrates below a stromal cell layer and self- 
renews to form a colony of cells, which resemble a cob- 
blestone in appearance [44,45]. Utilizing this technique, 
limiting dilutions of Granta SP and non-SP cells and 
CD133+/CD44+ and CD133−/CD44− cells were plated 
onto a semi-confluent monolayer of MS5 cells, chosen 
for its known role in supporting long term maintenance 
of HSCs in-vitro [45,46] and evaluated at weekly inter- 
vals for the presence of cobblestones. At the end of the 5 
week analysis, the CAFC frequencies of Granta CD133+/ 
CD44+ and CD133−/CD44− cells were not significantly 
different: 1/415 and 1/755 cells (P = 0.09) (Table 1), 
respectively. Granta SP cells, however, were enriched for 
stem cell-like cells, having a CAFC frequency of 1/970 
cells while non-SP cells had a CAFC frequency of 
1/4350 cells (P = 0.02) (Table 1). It is important to note 
that cell dilutions corresponding to 33,300, 11,100 and 
3700 cells/well were not included in SP and non-SP 
CAFC assays as they yielded non-responsive wells from 
non-SP cells, resulting in a shifted CAFC curve which 
could not be evaluated. It is possible that these high cell 
numbers may have overwhelmed the conditions of the 
assay. Figures 1(Ba) and 1(Bb) illustrate the presence 
and absence of cobblestones from Granta SP and non-SP 
cells, respectively.  
Interestingly, 1000 SP cells were observed to form 
spheres in the tumorsphere assay, a technique utilized to 
detect self-renewal of both stem cell populations and 
TICs [47-50]. These spheres were detected as early as 2 
weeks in culture (Figure 1(C)).  Lower limits of SP 
cells (1, 10 and 100) and all tested dilutions of non-SP 
cells (1, 10, 100 and 1000) were not observed to form 
tumorpheres. An example illustrating the absence of 
spheres and identifiable cells is shown for a culture of 
1000 non-SP cells (Figure 1(C)). Together, the CAFC 
and tumorsphere results suggest that Granta SP cells are 
enriched for self-renewing TICs at a dilution which cor- 
responds to a frequency of ~1000 cells. 
3.3. Matrigel Enhances the CAFC  
Frequencies of SP and Non-SP Cells 
Since ECM components have been shown to maintain 
certain stem cell populations in an undifferentiated state 
[35,51,52], we hypothesized that the addition of Matrigel 
would enhance the number of self-renewing TICs and 
thus the CAFC frequencies of putative SP and CD133+/ 
CD44+ TICs. Limiting dilutions of Granta SP and non-SP 
cells (33,300 cells/well to 1 cell/well) and CD133+/ 
CD44+ and CD133−/CD44− cells (407 cells/ well to 1 
cell/well) were plated onto MS5 cells and the cultures 
were overlaid with a final concentration of 275 μg/ml of 
Matrigel. Interestingly, the addition of Matrigel to Gran- 
ta SP and non-SP/MS5 co-cultures not only significant- 
ly increased the CAFC frequencies of both populations, 
but resulted in intersecting CAFC frequencies of 1/175 
for both SP and non-SP cells (P > 0.05) (Table 1) (Fig- 
ure 1(D)). Surprisingly, the addition of Matrigel to 
CD133+/CD44+ and CD133−/CD44−/MS5 co-cultures 
ignificantly decreased the CAFC frequencies to 1/4850  s 
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Figure 1. Granta possess populations of cells with stem cell-like properties. (Aa) The SP phenotype was identified in Granta 
cells and occurred at a frequency of 6.4% ± 1.8% (range: 0% - 35.2%) of the population. (Ab) Verapamil confirmed the pres- 
ence of SP cells. (Ac) Quadrants for the analysis of CD133/CD44-expressing cells were defined in unstained Granta cells. (Ad) 
CD133+/CD44+ cells, indicated by the oval in Q2, were present in Granta cells and occurred at a frequency of 0.06% ± 0.03% 
(range: 0% - 0.39%). (B) Images illustrating the presence of phase-dark cobblestones (indicated by the black arrows) from a 2 
week culture of SP/MS5 cells and absence of cobblestones from non-SP/MS5 cells maintained in culture for 5 weeks. Images 
were captured at ×100 magnification. (C) The presence of a tumorsphere was observed from 1000 SP cells maintained in cul-
ture for 2 weeks. Tumorsphere formation was not observed from 1000 non-SP cells maintained in culture for 6 weeks. Images 
were captured at ×200 magnification. (D) The CAFC frequencies of Granta SP and non-SP cells overlaid with 275 μg/ml Ma-
trigel is demarcated by the line representing 37% non-responding wells and was determined to be 1/175 cells for both cell 
populations. 95% confidence intervals are indicated by the error bars. *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001. 
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Table 1. Granta TIC and non-TIC CAFC frequencies. 
Cell Type Treatment CAFC Frequency Student’s T-test 
CD133+/CD44+ No Treatment  Matrigel 
1/415 
1/4 850 
 
<0.01 
CD133−/CD44− No Treatment  Matrigel 
1/755 
1/2 575 
 
<0.01 
SP No Treatment  Matrigel 
1/970 
1/175 
 
<0.01 
Non-SP No Treatment  Matrigel 
1/4 350 
1/175 
 
<0.01 
 
and 1/2575, respectively, in comparison to co-cultures 
without Matrigel (P < 0.01) (Table 1). Together, these 
data not only demonstrate that Matrigel has opposing 
effects on the CAFC frequencies of SP and non-SP cells 
and CD133+/CD44+ and CD133−/CD44− cells, but addi- 
tionally demonstrates that micro-environmental compo- 
nents, rather than phenotype differences, may be a more 
important factor in promoting stem cell-like behaviors of 
Granta SP and non-SP cells.  
3.4. Matrigel Expedites Tumor Formation of 
Granta SP and Non-SP Cells 
We sought to determine whether Matrigel enhanced 
the tumorigenic properties of Granta SP and CD133+/ 
CD44+ cells, a property reported by others [38-40]. Pal- 
pable tumors from Matrigel injections of 10, 100 and 
1000 SP and non-SP cells were evident in 100% of tested 
cases and arose within an average time of 34 ± 0.9 days 
following cell injection. Examples of tumors derived 
from the injections of 10 Matrigel-mixed SP and 10 Ma- 
trigel-mixed non-SP cells are shown (Figures 2(Aa) and 
2(Ab)). Remarkably, a tumor arose from the injection of 
a single Matrigel-mixed SP cell at 70 days post injection 
(Figures 2(Ac) and 2(B)). Tumors did not; however, 
arise from single cell injections of Matrigel-mixed non- 
SP cells at 160 days post-injection. Overall, significant 
differences in tumor volumes between Matrigel-mixed 
SP and non-SP cells were not observed (Figure 2(C)). In 
the absence of Matrigel, tumors arose in two animals 
injected with 1000 and 100 vehicle-mixed SP cells; how- 
ever, the tumor volumes were 2.4× and 1.4× less than 
their counterpart Matrigel-mixed tumors, respectively. 
Tumors did not develop from vehicle-injected non-SP 
cells nor did they form from control Matrigel or vehicle 
injections, demonstrating that these inoculums were not 
tumorigenic alone. Figure 2(D) depicts the frequency of 
tumor formation in Matrigel and vehicle-mixed SP and 
non-SP cells. CD133+/CD44+ and CD133−/CD44− cells 
were also evaluated for their tumor-forming capabilities. 
Both cell populations were injected into NSG mice in the 
presence and absence of Matrigel or hyaluronan, chosen 
as CD44 preferentially interacts with hyaluronan [22]. 
Table 2 provides a summary of findings from Matrigel 
and vehicle-mixed injections of SP and non-SP cells. 
Surprisingly, tumors did not arise by 160 days post-injec- 
tion from Matrigel and hyaluronan-mixed CD133+/ 
CD44+ and CD133−/CD44− cells (data not shown). Simi- 
larly, vehicle-mixed injections of CD133+/CD44+ and 
CD133−/CD44− cells did not give rise to tumors at 160 
days post-injection. Taken together, these results suggest 
that phenotypic differences in tumor formation from SP 
and non-SP cells may be irrelevant in the presence of 
Matrigel but may be necessary for tumor establishment 
and growth in the absence of Matrigel. CD133+/CD44+ 
and CD133−/CD44− cells are not capable of tumor for- 
mation under the tested conditions. 
In order to validate that tumors obtained from SP and 
non-SP cells were from Granta cells, flow cytometry was 
employed to quantify cell surface CD20. Flow cytometry 
detected enriched levels of CD20 positive cells from SP 
and non-SP-derived tumors (Figures 2(Ea) and (Eb)). 
SP and non-SP-derived tumors had an average tumor 
CD20 expression of 82% ± 6%. Together, these data 
confirm that tumor specimens were derived from human 
MCL cells. 
3.5. SP Fractions Were Identified in SP and  
Non-SP Derived Tumors 
Flow cytometry was utilized to assess the presence of 
the SP in Matrigel-mixed SP and non-SP-derived tumors. 
SP fractions were found in tumors arising from injections 
of both SP (Figure 2(Ec)) and non-SP cells (Figure 
2(Ed)). The mean SP expression was the same for tu- 
mors derived from Matrigel-mixed SP and non-SP cells: 
1.1% ± 0.5% and 1.1% ± 0.3%, respectively (P = 0.4) 
and was 1.4% ± 0.7% in vehicle-mixed SP cells (P > 0.05: 
Matrigel-mixed non-SP and SP-derived tumors). To- 
gether, these data strongly suggest that the SP phenotype 
is malleable and may be modulated by microenviron- 
mental factors.  
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3.6. SP and Non-SP Derived Tumors Cells  
Are Capable of Spread to Distant  
Organs 
In order to evaluate the metastatic capabilities of SP 
and non-SP cells, several murine organs including the 
bone marrow, spleen, lung, small intestine, liver and 
kidney were harvested and assessed for the presence of 
tumor cells using H&E staining and flow cytometry. 
H&E staining did not reveal the presence of distinct 
tumor nodules in any of the tissues examined (data not 
shown). Given the limitations of H&E/immunostaining 
to small regions of tissue sections, we elected to utilize 
flow cytometry on intact, prepared tissues to investigate 
whether human CD20 cells, indicative of metastasizing 
Granta cells, were present in the aforementioned organs. 
Human CD20-positive cells were detected by flow 
cytometry in all evaluated tissues, with the greatest level 
of detection observed in the small intestine (Figure 3), a 
common metastatic site for non-Hodgkin’s lymphomas  
[53]. Taken together, these results indicate that while 
identifiable nodular tumors were not detected in potential 
metastatic sites, human CD20 expression was observed 
and quantified in murine tissues indicating that Granta 
cells from SP and non-SP injections most likely migrated 
to these distant sites. 
3.7. IL-8 Levels Are Significantly Elevated in  
Granta/MS5 Co-Cultures 
We examined IL-8 levels, chosen due to its implica-
tions in tumor invasion and metastasis [54], in the condi-
tioned media (CM) of Granta and MS5 cells after 3 and 6 
days in culture. IL-8 was also evaluated in Granta MS5 
co-cultures at several days along the culture period and 
was further investigated in co-cultures of Granta TIC and 
non-TIC populations with MS5 cells. IL-8 was found to 
be secreted at negligible levels from MS5 cells after 3 
(Figure 4(A)) and 6 days (data not shown) in culture and 
highly secreted from Granta cells after 3 (Figure 4(A))  
 
 
Figure 2. Tumor specimens and characteristics of Matrigel-mixed SP and non-SP cells. (A) Tumor specimens 
obtained from Matrigel-mixed 10 SP cells, 10 non-SP cells and 1 SP cell. Scale bars represent 1 cm. (B) NSG 
mouse harboring a tumor from the injection of a single Matrigel-mixed SP cell. (C) Tumor volumes were not 
statistically significantly different between SP and non-SP-derived tumors at corresponding dilutions. (D) The 
frequency of tumor formation was the same for all tested dilutions of Matrigel-mixed SP and non-SP cells and 
occurred 100% of the time. Tumor formation of vehicle-mixed SP cells occurred 33% of the time and did not 
result from vehicle-mixed non-SP cells. (E) Flow cytometry demonstrated the presence of cell surface CD20 
expression ((a) and (b)) and SPs ((c) and (d)) in tumors arising from 10 SP and 10 non-SP cells. 
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Table 2. Tumor Formation from Granta SP and non-SP cells. 
Cells Inoculum Tumor Formation (+/−) 1        10        100       1000 
Avg Weeks to Tumor Palpability 
1         10        100       1000 P value
Vehicle NA 0/4 1/3 1/3 NA NT 4.8 4.7 
SP 
Matrigel 1/5 4/4 3/3 3/3 10 5.2 ± 0.4 5 ± 0.3 4.4 ± 0.1 
0.003 
Vehicle NA 0/3 0/3 0/3 NA NT NT NT 
Non-SP 
Matrigel 0/5 4/4 3/3 3/3 NT 5.3 ± 0.2 4.7 ± 0.2 4.3 ± 0.04 
<0.001
N/A Not applicable; N/T No Tumor; Avg Average. 
 
 
Figure 3. Granta cells spread to distant murine tissues. 
CD20-positive cells were detected in all murine tissues 
from SP and non-SP-injected NSG mice. All values are 
averages and presented as a percentage of the total 
CD20-positive cells minus control. SMI: Small Inte- 
stine. BM: Bone Marrow. XP ≤ 0.05. 
 
and 6 days (data not shown) in culture. Interestingly, it 
was noted that the greatest level of IL-8 secretion oc 
curred in a time dependent manner in Granta/MS5 co- 
cultures (Figure 4(B)). Surprisingly, it was found that 
IL-8 secretion was significantly higher in SP/MS5 co- 
cultures than in non-SP/MS5 co-cultures where IL-8 was 
not detectable (Figure 4(C)). Regarding CD133+/ CD44+ 
and CD133−/CD44− cells co-cultured with MS5, IL-8 
was not significantly different (Figure 4(C)). Together, 
these studies suggest that MS5 cells alone do not secrete 
appreciable levels of IL-8, but significantly contribute to 
IL-8 levels when cultured in direct contact with Granta 
cells. Moreover, these results further suggest that IL-8 is 
predominantly secreted from co-cultures of SP/MS5, but 
not appreciably from co-cultures of MS5 with non-SP, 
CD133+/CD44+ and CD133−/CD44− cells.  
4. DISCUSSION 
Here, we report that the Granta MCL cell line pos- 
sesses subpopulations of cells expressing stem cell 
functions and markers. For the purpose of more closely 
mimicking the in-vivo environment, we evaluated the 
stem cell-like and tumor-forming capabilities of Granta 
SP and CD133+/CD44+ cells in the presence of micro- 
environmental components found in Matrigel. While 
numerous reports have documented the existence of rare 
sub-populations of TICs in a variety of carcinomas, the 
majority of these studies have failed to consider the role 
of the microenvironment in modulating the stem cell-like 
and tumor-forming properties of such cells. Thus, the 
question remains as to whether properties associated with 
TICs are mediated through mechanisms solely related to 
intrinsic or extrinsic factors, or some combination of 
both.  
Our results demonstrate that when assessed for the 
presence of stem and progenitor cells, evaluated using 
the CAFC assay, Granta SP cells were highly enriched 
for stem cell-like cells. The ability of Granta cell popu- 
lations to form cobblestones in the CAFC assay is in 
contrast to observations from Kurtova et al. (2009) who 
reported that Granta cells were incapable of cobblestone 
formation. It’s possible that this discrepancy may have 
arisen due to the type of fibroblasts used in these assays. 
For instance, it has been documented that certain murine 
and human fibroblast cell lines are incapable of support-
ing the long-term maintenance of human HSCs in-vitro 
[46,55,56]. Since the MS5 cell line has been shown to 
reliably support the quantification and long term main-
tenance of HSCs in-vitro [45,46], we employed this cell 
line for analyses of stem and progenitor cell frequencies 
and believe it to be a valid cell line for this purpose. In 
this manner, our data not only demonstrates that the SP 
isolation technique better enriches for cells possessing 
stem cell-like properties in Granta, but warrants caution 
in the choice of fibroblast cell lines for the purpose of 
identifying and/or supporting putative stem cell popula-
tions.  
Further investigating the in-vitro stem cell-like 
properties of putative Granta TIC cells, we observed that 
Matrigel had discordant effects on SP and CD133+/ 
CD44+ cells, enhancing and depressing the CAFC 
frequencies, respectively. Interestingly, Matrigel endowed 
both SP and non-SP cells with a concordantly enriched  
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(a) 
 
(b)                                                   (c) 
Figure 4. IL-8 secretion was significantly elevated in Granta and co-cultures of Granta and Granta SP with MS5. 
Secreted IL-8 was significantly elevated in (A) Granta CM (B) Granta/MS5 CM, with increasing IL-8 observed 
during the culture period. All comparisons were made against baseline (day 1) IL-8 secretion. (C) IL-8 secretion 
was significantly elevated in SP/MS5 co-cultures and was negligibly detected in non-SP/MS5 co-cultures. 
Detectable IL-8 was observed from CD133−/CD44− /MS5 co-cultures, but was negligibly secreted from 
CD133+/CD44+ /MS5 co-cultures . XP ≤ 0.05; XXP ≤ 0.01; XXXP ≤ 0.001. 
 
proportion of cells exhibiting a stem cell phenotype. A 
similar observation was made by Cao et al. [57] who 
reported that non-SP cells in nasopharyngeal carcinomas 
could be induced to express the SP phenotype when 
cultured in the conditioned media of macrophage-like 
cells, a cell type comprising the microenvironment. Our 
results suggest that the microenvironment plays an 
important role in modulating a stem cell-like phenotype 
of Granta SP and non-SP cells. Matrigel did not, however, 
enrich for stem cell-like cells in the CD133+/CD44+ 
population. It’s possible that Matrigel may not have pro- 
vided the requisite ECM constituents for facilitating a 
stem cell phenotype. For instance, the main ligand for 
CD44 is HA [22], a polysaccharide ECM component 
reported to be enriched in the tumor microenvironment 
[58]. Since Matrigel does not contain HA, it’s possible 
that the Matrigel niche does not provide the cues nece- 
ssary to support the expression of a stem cell-like pheno- 
type from CD133+/CD44+ cells. However, it should be 
noted that CD133+/CD44+ may not enrich for a popu- 
lation of MCL TICs as evaluated in the CAFC assay.  
Recent reports have documented the tumor-forming 
capabilities of Matrigel-injected TICs [38-40]. Utilizing 
similar techniques, we demonstrated that both Matrigel- 
mixed SP and non-SP cells were tumorigenic in NSG 
mice at dilutions of 10 or more cells. Indeed, the micro- 
environment-mediated control of tumorigenesis is a 
widely acknowledged phenomenon for unselected tumor 
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cells [59,60] and was reported for thyroid [61] and mes- 
enchymal [62] TICs. In the latter studies, Matrigel- 
mixed SP and non-SP cells were reported to form tumors 
in immunocompromised mice [61,62]. While these au- 
thors did not attribute their observations to a microenvi- 
ronment-mediated effect, it is likely, given our data, that 
the ECM factors found in Matrigel is a more important 
determinant for influencing tumor formation than SP and 
non-SP cell phenotype differences. In the absence of 
Matrigel, intrinsic differences may be important as tumor 
formation was documented in two instances from vehi- 
cle-injected SP cells. Together, these observations would 
suggest that both intrinsic and extrinsic properties may 
govern tumor-forming capabilities of Granta SP and 
non-SP cells. A remarkable observation was the finding 
that a tumor arose from 1 Matrigel-injected SP cell. 
While tumors arose in 1/5 cases from the injections of 
single Matrigel-mixed SP cells, our results are consistent 
with that of Quintana et al [60], who observed a ~20% 
tumor formation frequency from the injection of single 
Matrigel-mixed melanoma cells. Regarding the absence 
of tumors from single cell injections of Matrigel-mixed 
non-SP cells, we speculate that intrinsic mechanisms 
may provide a tumorigenic advantage to SP cells. This 
potentially suggests that interactions and communica- 
tions between tumor cells may be an important means by 
which non-SP cells form tumors. In future studies, it will 
be necessary to address the limiting number of non-SP 
cells which can reliably form tumors in NSG mice. 
The presence of a SP denotes a population of cells ca-
pable of self-renewal [27]. We discovered that SP cells 
were found in tumors derived from Matrigel-mixed SP 
and non-SP injections. The presence of the SP in Ma- 
trigel-mixed non-SP tumors was unexpected and may 
relate to the transformation ability of Matrigel as previ- 
ously demonstrated in thyroid cancer cells [61]. This 
assessment is reasonable when taking into consideration 
the in-vitro results whereby Matrigel significantly en- 
hanced the CAFC frequency of non-SP cells. Together, 
these data strongly suggest that the SP phenotype is mal- 
leable and may be modulated by micro-environmental 
factors. It will be necessary to determine whether this 
phenomenon is due to the microenvironment-mediated 
release of cytokines/chemokines or the acquisition of 
epigenetic changes facilitating cellular transformation of 
the target cells. 
Metastasis is the greatest determinant of cancer mor- 
bidity. Although solid tumor nodules were not detected, 
diffuse infiltrates of MCL cells were present in all 
murine tissues examined. While it is unknown as to what 
caused the discrepancy between the lack of nodular tu- 
mor formation in spite of the cellular presence of Granta 
MCL cells, we hypothesize that cellular to microenviron- 
ment interactions likely play a role. In other words, 
Granta SP and non-SP cells were incapable of forming 
the appropriate cellular to cellular or non-cellular asso- 
ciations due to host microenvironment-mediated incom- 
patibilities, a postulate set forth by Kelly et al. [63]. In 
this manner, tumor development could not take place 
despite the presence of MCL cells. It will be important to 
address whether an orthotopic introduction of a carefully 
selected human-derived stromal cell line, with Granta SP 
and non-SP cells may overcome potential species incom- 
patibility constraints.  
Neither CD133+/CD44+ nor CD133−/CD44− cells co- 
mixed with Matrigel or hyaluronan formed tumors. It is 
possible that either the cell populations themselves and/ 
or the microenvironmental niches were not favorable for 
growth of these cell populations into tumors. Since hya- 
luronan principally mediates cellular interactions with 
CD44 [22], it is puzzling as to why tumors did not 
develop from CD133+/CD44+ cells. Given the absence of 
sequestered growth factors in the hyaluronan matrix, it is 
possible that hyaluronan in combination with growth 
factors is necessary for tumor formation from CD133+/ 
CD44+. In future studies, it will be important to evaluate 
how a hyaluronan-rich matrix containing growth factors 
influence tumor development from Granta CD133+/ 
CD44+ cells.  
In conclusion, our results demonstrate that the ECM 
constituents found in Matrigel are pivotal for stem cell- 
like and tumor-forming properties of Granta SP and non- 
SP cells. Additionally, these data point to potential niche 
specifications regarding the manifestation of tumor for- 
mation and stem cell-like properties associated with 
given subpopulations of tumor cells. Importantly, these 
data warrant caution in assigning tumor-forming capa- 
bilities exclusively to rare TICs. 
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